Funder
Janssen Scientific Affairs
Publisher
Springer Science and Business Media LLC
Reference7 articles.
1. Blauvelt A, Garrelts A, Malatestinic W, Birt J, Zhu B, Feely M. Response to Fitzgerald T, et al. Long-term psoriasis control with guselkumab, adalimumab, secukinumab, or ixekizumab in the USA. Dermatol Ther (Heidelb). 2023. (in press)
2. Fitzgerald T, Zhdanava M, Pilon D, et al. Long-term psoriasis control with guselkumab, adalimumab, secukinumab, or ixekizumab in the USA. Dermatol Ther (Heidelb). 2023;13(4):1053–68. https://doi.org/10.1007/s13555-023-00910-6.
3. Xu C, Ferrante SA, Fitzgerald T, Pericone CD, Wu B. Inconsistencies in the days supply values reported in pharmacy claims databases for biologics with long maintenance intervals. J Manag Care Spec Pharm. 2023;29(1):90–100. https://doi.org/10.18553/jmcp.2023.29.1.90.
4. Zhdanava M, Fitzgerald T, Pilon D, et al. Long term psoriasis control with guselkumab versus secukinumab and ixekizumab: analysis of drug persistence in large claims database. presented at: Fall Clinical Dermatology Annual Meeting; October 20–23, 2022 Las Vegas, NV.
5. Hainmueller J. Entropy balancing for causal effects: a multivariate reweighting method to produce balanced samples in observational studies. Polit Anal. 2012;20(1):25–46. https://doi.org/10.1093/pan/mpr025.